Study to Assess Absolute Bioavailability of TAK-935 (OV935) and to Characterize Mass Balance, Pharmacokinetics, Metabolism, and Excretion of [14C]TAK-935 (OV935) in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 9, 2020

Primary Completion Date

August 18, 2020

Study Completion Date

August 18, 2020

Conditions

Healthy Volunteers

Interventions

DRUG

TAK-935 Oral Tablet

TAK-935 tablet

DRUG

[14C]TAK-935 IV Infusion

\[14C\]TAK-935 IV infusion

DRUG

[14C]TAK-935 Oral Solution

\[14C\]TAK-935 oral solution

Trial Locations (1)

Celerion, Lincoln